JP2021520349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021520349A5 JP2021520349A5 JP2020553633A JP2020553633A JP2021520349A5 JP 2021520349 A5 JP2021520349 A5 JP 2021520349A5 JP 2020553633 A JP2020553633 A JP 2020553633A JP 2020553633 A JP2020553633 A JP 2020553633A JP 2021520349 A5 JP2021520349 A5 JP 2021520349A5
- Authority
- JP
- Japan
- Prior art keywords
- ret
- cancer
- composition according
- composition
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 230000008707 rearrangement Effects 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 34
- 230000035772 mutation Effects 0.000 claims description 28
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 26
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 26
- 230000004927 fusion Effects 0.000 claims description 21
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims description 18
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 18
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 12
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 201000002510 thyroid cancer Diseases 0.000 claims description 12
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 12
- 229940125904 compound 1 Drugs 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 238000009169 immunotherapy Methods 0.000 claims description 6
- 208000007312 paraganglioma Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010055114 Colon cancer metastatic Diseases 0.000 claims description 4
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 claims description 4
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 102200006099 rs79658334 Human genes 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 4
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 229960001292 cabozantinib Drugs 0.000 claims description 3
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 3
- 102200006308 rs74799832 Human genes 0.000 claims description 3
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000021309 Germ cell tumor Diseases 0.000 claims description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 101150077555 Ret gene Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 229940028652 abraxane Drugs 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical group [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 229960003784 lenvatinib Drugs 0.000 claims description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical group C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 102200006166 rs77709286 Human genes 0.000 claims description 2
- 102200006097 rs79658334 Human genes 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 54
- 102200006361 rs79781594 Human genes 0.000 claims 3
- 102220007191 rs143795581 Human genes 0.000 claims 2
- 102200006358 rs76262710 Human genes 0.000 claims 2
- 102200006359 rs76262710 Human genes 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 102220618619 Arginine-glutamic acid dipeptide repeats protein_V804E_mutation Human genes 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 1
- 101000866633 Homo sapiens Protein Hook homolog 3 Proteins 0.000 claims 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 claims 1
- 102100031717 Protein Hook homolog 3 Human genes 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- 102220367971 c.2647G>T Human genes 0.000 claims 1
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 102200062343 rs118203721 Human genes 0.000 claims 1
- 102220007192 rs146646971 Human genes 0.000 claims 1
- 102220335404 rs1554818786 Human genes 0.000 claims 1
- 102200055821 rs201486601 Human genes 0.000 claims 1
- 102200034108 rs28933683 Human genes 0.000 claims 1
- 102200004573 rs377767391 Human genes 0.000 claims 1
- 102200004574 rs377767391 Human genes 0.000 claims 1
- 102200004575 rs377767391 Human genes 0.000 claims 1
- 102200004571 rs377767396 Human genes 0.000 claims 1
- 102200004579 rs377767397 Human genes 0.000 claims 1
- 102220007170 rs377767397 Human genes 0.000 claims 1
- 102220007176 rs377767404 Human genes 0.000 claims 1
- 102200006195 rs377767405 Human genes 0.000 claims 1
- 102200006197 rs377767405 Human genes 0.000 claims 1
- 102200006198 rs377767405 Human genes 0.000 claims 1
- 102220010316 rs377767409 Human genes 0.000 claims 1
- 102220007209 rs377767424 Human genes 0.000 claims 1
- 102200006109 rs377767429 Human genes 0.000 claims 1
- 102220009701 rs377767439 Human genes 0.000 claims 1
- 102200006107 rs55947360 Human genes 0.000 claims 1
- 102220007210 rs55947360 Human genes 0.000 claims 1
- 102200006093 rs75030001 Human genes 0.000 claims 1
- 102200006161 rs75076352 Human genes 0.000 claims 1
- 102200006164 rs75996173 Human genes 0.000 claims 1
- 102200006167 rs75996173 Human genes 0.000 claims 1
- 102200006205 rs75996173 Human genes 0.000 claims 1
- 102200006191 rs77503355 Human genes 0.000 claims 1
- 102200006362 rs77503355 Human genes 0.000 claims 1
- 102200004570 rs77558292 Human genes 0.000 claims 1
- 102200004635 rs77558292 Human genes 0.000 claims 1
- 102220007154 rs77558292 Human genes 0.000 claims 1
- 102200004572 rs77939446 Human genes 0.000 claims 1
- 102220010204 rs77939446 Human genes 0.000 claims 1
- 102200006360 rs79781594 Human genes 0.000 claims 1
- 102200004577 rs80069458 Human genes 0.000 claims 1
- 102220095273 rs876658138 Human genes 0.000 claims 1
- 201000003804 salivary gland carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- 230000008521 reorganization Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100027274 Dual specificity protein phosphatase 6 Human genes 0.000 description 1
- 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 description 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 description 1
- 101001057587 Homo sapiens Dual specificity protein phosphatase 6 Proteins 0.000 description 1
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 description 1
- 101000629617 Homo sapiens Protein sprouty homolog 4 Proteins 0.000 description 1
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 102100026845 Protein sprouty homolog 4 Human genes 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024334 diffuse gastric cancer Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102220265292 rs570176656 Human genes 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021199945A JP2022022391A (ja) | 2018-04-03 | 2021-12-09 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| JP2023167564A JP2023165937A (ja) | 2018-04-03 | 2023-09-28 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652284P | 2018-04-03 | 2018-04-03 | |
| US62/652,284 | 2018-04-03 | ||
| US201862656297P | 2018-04-11 | 2018-04-11 | |
| US62/656,297 | 2018-04-11 | ||
| US201862657605P | 2018-04-13 | 2018-04-13 | |
| US62/657,605 | 2018-04-13 | ||
| US201862741683P | 2018-10-05 | 2018-10-05 | |
| US62/741,683 | 2018-10-05 | ||
| PCT/US2019/025655 WO2019195471A1 (en) | 2018-04-03 | 2019-04-03 | Ret inhibitor for use in treating cancer having a ret alteration |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199945A Division JP2022022391A (ja) | 2018-04-03 | 2021-12-09 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| JP2023167564A Division JP2023165937A (ja) | 2018-04-03 | 2023-09-28 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520349A JP2021520349A (ja) | 2021-08-19 |
| JP2021520349A5 true JP2021520349A5 (enExample) | 2021-09-30 |
| JP7422084B2 JP7422084B2 (ja) | 2024-01-25 |
Family
ID=66223846
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020553633A Active JP7422084B2 (ja) | 2018-04-03 | 2019-04-03 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| JP2021199945A Pending JP2022022391A (ja) | 2018-04-03 | 2021-12-09 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| JP2023167564A Withdrawn JP2023165937A (ja) | 2018-04-03 | 2023-09-28 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199945A Pending JP2022022391A (ja) | 2018-04-03 | 2021-12-09 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| JP2023167564A Withdrawn JP2023165937A (ja) | 2018-04-03 | 2023-09-28 | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20210100795A1 (enExample) |
| EP (2) | EP3773589B1 (enExample) |
| JP (3) | JP7422084B2 (enExample) |
| KR (1) | KR20200139749A (enExample) |
| AU (1) | AU2019247766A1 (enExample) |
| BR (1) | BR112020020273A2 (enExample) |
| CA (1) | CA3096043A1 (enExample) |
| CL (1) | CL2020002544A1 (enExample) |
| CR (1) | CR20200522A (enExample) |
| DK (1) | DK3773589T3 (enExample) |
| ES (1) | ES2970041T3 (enExample) |
| FI (1) | FI3773589T3 (enExample) |
| HR (1) | HRP20240124T1 (enExample) |
| HU (1) | HUE065374T2 (enExample) |
| IL (1) | IL277629A (enExample) |
| LT (1) | LT3773589T (enExample) |
| MX (1) | MX2020010417A (enExample) |
| MY (1) | MY203645A (enExample) |
| PE (1) | PE20210096A1 (enExample) |
| PL (1) | PL3773589T3 (enExample) |
| PT (1) | PT3773589T (enExample) |
| RS (1) | RS65127B1 (enExample) |
| SG (1) | SG11202009681YA (enExample) |
| SI (1) | SI3773589T1 (enExample) |
| WO (1) | WO2019195471A1 (enExample) |
| ZA (1) | ZA202006072B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| FI3773589T3 (fi) | 2018-04-03 | 2024-02-01 | Blueprint Medicines Corp | Ret-estäjä käytettäväksi ret-muunnoksen sisältävän syövän hoidossa |
| US11666570B2 (en) * | 2019-07-11 | 2023-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnosis and regulation of epidermal differentiation and cancer cell activity |
| US12448366B2 (en) | 2020-05-29 | 2025-10-21 | Rigel Pharmaceuticals, Inc. | Solid forms of pralsetinib |
| US11946935B2 (en) * | 2020-08-25 | 2024-04-02 | Regents Of The University Of Minnesota | Circulating tumor markers for meningiomas |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003532635A (ja) | 2000-02-17 | 2003-11-05 | アムジエン・インコーポレーテツド | キナーゼ阻害薬 |
| BR0312873A (pt) | 2002-07-24 | 2005-06-28 | Univ Cincinnati | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante |
| PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| CA2607617A1 (en) | 2005-05-09 | 2006-11-16 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| US20100047777A1 (en) | 2005-05-26 | 2010-02-25 | The Johns Hopkins University | Methods for identifying mutations in coding and non-coding dna |
| WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
| US20090227598A1 (en) | 2006-01-24 | 2009-09-10 | Buser-Doepner Carolyn A | Ret Tyrosine Kinase Inhibition |
| CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US20090048214A1 (en) | 2006-11-15 | 2009-02-19 | Rigel Pharmaceuticals, Inc | Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds |
| WO2009003136A1 (en) | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| AU2008279776B2 (en) | 2007-07-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
| US8629135B2 (en) | 2008-07-14 | 2014-01-14 | Queen's University At Kingston | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer |
| US8367690B2 (en) | 2009-03-24 | 2013-02-05 | Vertex Pharmaceuticals Inc. | Aminopyridine derivatives having aurora a selective inhibitory action |
| EP2440052A4 (en) | 2009-06-08 | 2013-01-23 | Abraxis Bioscience Llc | TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF |
| KR20120026612A (ko) | 2009-06-09 | 2012-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 벤질 치환 트리아진 유도체와 이들의 치료적 용도 |
| MX2012005023A (es) | 2009-10-30 | 2012-06-19 | Ariad Pharma Inc | Metodos y composiciones para tratar cancer. |
| CA2780892C (en) | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
| KR20140047138A (ko) | 2011-08-04 | 2014-04-21 | 도쿠리츠교세이호진 고쿠리츠간켄큐센터 | Ｋｉｆ5ｂ 유전자와 ｒｅｔ 유전자와의 융합 유전자, 및 당해 융합 유전자를 표적으로 한 암 치료의 유효성을 판정하는 방법 |
| SG2014012728A (en) | 2011-08-23 | 2014-06-27 | Foundation Medicine Inc | Novel kif5b-ret fusion molecules and uses thereof |
| MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
| US20130096136A1 (en) | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
| US10023855B2 (en) | 2011-10-31 | 2018-07-17 | Macrogen, Inc. | Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker |
| WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| EP2824099A4 (en) | 2012-03-09 | 2015-11-11 | Carna Biosciences Inc | NOVEL TRIAZINE DERIVATIVE |
| JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ｒｅｔ融合体の検出法 |
| TWI577677B (zh) | 2012-04-25 | 2017-04-11 | 拉夸里亞創藥股份有限公司 | 作爲ｔｔｘ－ｓ阻斷劑之吡咯並吡啶酮衍生物 |
| EP2849751A1 (en) | 2012-05-10 | 2015-03-25 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| RU2679130C2 (ru) | 2012-07-11 | 2019-02-06 | Блюпринт Медсинс Корпорейшн | Ингибиторы рецептора фактора роста фибробластов |
| WO2014017491A1 (ja) | 2012-07-26 | 2014-01-30 | 独立行政法人国立がん研究センター | Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子 |
| ES2726605T3 (es) | 2012-09-07 | 2019-10-08 | Exelixis Inc | Inhibidores de MET, VEGFR y RET para usar en el tratamiento del adenocarcinoma de pulmón |
| CA3077553C (en) | 2012-09-25 | 2022-08-02 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitor |
| CN104870446B (zh) | 2012-11-07 | 2019-08-13 | 内尔维阿诺医学科学有限公司 | 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途 |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| BR112015019590A2 (pt) | 2013-02-25 | 2017-07-18 | Bristol Myers Squibb Co | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv |
| EP2970191B1 (en) | 2013-03-15 | 2016-12-21 | GlaxoSmithKline Intellectual Property Development Limited | Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2014147640A2 (en) | 2013-03-19 | 2014-09-25 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of anagliptin |
| WO2015006875A1 (en) | 2013-07-18 | 2015-01-22 | Methylgene Inc. | Process for the preparation of substituted pyrimidines |
| CN105658814A (zh) | 2013-08-20 | 2016-06-08 | 日本国立癌症研究中心 | 在肺癌中检测出的新型融合基因 |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| SG11201602937UA (en) | 2013-10-17 | 2016-05-30 | Blueprint Medicines Corp | Compositions useful for treating disorders related to kit |
| EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| UA122213C2 (uk) | 2014-09-10 | 2020-10-12 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Сполуки як інгібітори кінази, реаранжованої під час трансфекції (ret) |
| UA123084C2 (uk) | 2014-09-10 | 2021-02-17 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Сполуки як інгібітори кінази, реаранжованої під час трансфекції (ret) |
| AU2015345054B2 (en) | 2014-11-14 | 2020-03-05 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| CN104844567B (zh) | 2015-04-23 | 2017-03-29 | 暨南大学 | 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法 |
| PL3322706T3 (pl) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| HK1255330A1 (zh) | 2015-08-26 | 2019-08-16 | 缆图药品公司 | 适用於治疗与ntrk相关的病症的化合物和组合物 |
| CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| BR112018008908A2 (pt) | 2015-11-02 | 2018-11-27 | Janssen Pharmaceutica Nv | anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos |
| KR20180069903A (ko) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
| TWI733713B (zh) | 2015-11-19 | 2021-07-21 | 美商纜圖藥品公司 | 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物 |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| SG10202009589UA (en) | 2016-04-01 | 2020-10-29 | Signal Pharm Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| CN115650985B (zh) | 2016-04-15 | 2024-08-02 | 癌症研究科技有限公司 | 作为ret激酶抑制剂的杂环化合物 |
| SG11201808907PA (en) | 2016-04-15 | 2018-11-29 | Blueprint Medicines Corp | Inhibitors of activin receptor-like kinase |
| WO2017178845A1 (en) | 2016-04-15 | 2017-10-19 | Cancer Research Technology Limited | Heterocyclic compounds as ret kinase inhibitors |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| JP2018052878A (ja) | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| CN106749231B (zh) | 2016-10-09 | 2019-03-01 | 南京纳丁菲医药科技有限公司 | 萘啶化合物和药物组合物及它们的应用 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| US10799503B2 (en) | 2016-12-01 | 2020-10-13 | Ignyta, Inc. | Methods for the treatment of cancer |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
| JP2020519672A (ja) * | 2017-05-15 | 2020-07-02 | ブループリント メディシンズ コーポレイション | ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 |
| US10934300B2 (en) | 2017-06-23 | 2021-03-02 | San Diego State University (Sdsu) Foundation | Atropisomerism for enhanced kinase inhibitor selectivity |
| CN109180677A (zh) | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
| AU2018298443B2 (en) | 2017-07-07 | 2024-11-21 | Medicover Public Co Ltd | Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers |
| CN107980784B (zh) | 2017-12-13 | 2020-05-26 | 中国农业大学 | 5-氨基吡唑类化合物在调节植物生长方面的应用 |
| JOP20200152A1 (ar) | 2017-12-19 | 2022-10-30 | Turning Point Therapeutics Inc | مركبات حلقية كبرى لعلاج مرض |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CN108341782A (zh) | 2018-03-30 | 2018-07-31 | 南京哈柏医药科技有限公司 | 3-氨基-5-甲基吡唑的合成工艺 |
| FI3773589T3 (fi) | 2018-04-03 | 2024-02-01 | Blueprint Medicines Corp | Ret-estäjä käytettäväksi ret-muunnoksen sisältävän syövän hoidossa |
| JP7490635B2 (ja) | 2018-08-10 | 2024-05-27 | ブループリント メディシンズ コーポレイション | Ｅｇｆｒ変異がんの処置 |
| CN111440151A (zh) | 2020-03-25 | 2020-07-24 | 魏威 | 制备抗肿瘤药普拉赛替尼的方法 |
| CN111362923A (zh) | 2020-03-25 | 2020-07-03 | 魏威 | 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法 |
| US12448366B2 (en) | 2020-05-29 | 2025-10-21 | Rigel Pharmaceuticals, Inc. | Solid forms of pralsetinib |
| IL298525A (en) | 2020-05-29 | 2023-01-01 | Blueprint Medicines Corp | Pralsetinib pharmaceutical compositions |
| WO2022120136A1 (en) | 2020-12-04 | 2022-06-09 | Blueprint Medicines Corporation | Method of preparing pralsetinib |
-
2019
- 2019-04-03 FI FIEP19718531.7T patent/FI3773589T3/fi active
- 2019-04-03 PT PT197185317T patent/PT3773589T/pt unknown
- 2019-04-03 EP EP19718531.7A patent/EP3773589B1/en active Active
- 2019-04-03 SI SI201930702T patent/SI3773589T1/sl unknown
- 2019-04-03 SG SG11202009681YA patent/SG11202009681YA/en unknown
- 2019-04-03 ES ES19718531T patent/ES2970041T3/es active Active
- 2019-04-03 KR KR1020207031426A patent/KR20200139749A/ko not_active Withdrawn
- 2019-04-03 BR BR112020020273-8A patent/BR112020020273A2/pt not_active Application Discontinuation
- 2019-04-03 PE PE2020001523A patent/PE20210096A1/es unknown
- 2019-04-03 US US17/044,884 patent/US20210100795A1/en not_active Abandoned
- 2019-04-03 CR CR20200522A patent/CR20200522A/es unknown
- 2019-04-03 RS RS20240107A patent/RS65127B1/sr unknown
- 2019-04-03 MX MX2020010417A patent/MX2020010417A/es unknown
- 2019-04-03 WO PCT/US2019/025655 patent/WO2019195471A1/en not_active Ceased
- 2019-04-03 AU AU2019247766A patent/AU2019247766A1/en not_active Withdrawn
- 2019-04-03 LT LTEPPCT/US2019/025655T patent/LT3773589T/lt unknown
- 2019-04-03 HU HUE19718531A patent/HUE065374T2/hu unknown
- 2019-04-03 DK DK19718531.7T patent/DK3773589T3/da active
- 2019-04-03 HR HRP20240124TT patent/HRP20240124T1/hr unknown
- 2019-04-03 PL PL19718531.7T patent/PL3773589T3/pl unknown
- 2019-04-03 CA CA3096043A patent/CA3096043A1/en active Pending
- 2019-04-03 JP JP2020553633A patent/JP7422084B2/ja active Active
- 2019-04-03 EP EP23199171.2A patent/EP4353317A3/en not_active Withdrawn
- 2019-04-03 MY MYPI2020005148A patent/MY203645A/en unknown
-
2020
- 2020-09-27 IL IL277629A patent/IL277629A/en unknown
- 2020-09-30 ZA ZA2020/06072A patent/ZA202006072B/en unknown
- 2020-10-01 CL CL2020002544A patent/CL2020002544A1/es unknown
- 2020-10-02 US US17/061,743 patent/US11963958B2/en active Active
- 2020-12-18 US US17/127,041 patent/US11273160B2/en active Active
-
2021
- 2021-07-16 US US17/377,885 patent/US11872192B2/en active Active
- 2021-12-09 JP JP2021199945A patent/JP2022022391A/ja active Pending
-
2023
- 2023-09-28 JP JP2023167564A patent/JP2023165937A/ja not_active Withdrawn
-
2024
- 2024-03-15 US US18/606,346 patent/US20250041297A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520349A5 (enExample) | ||
| JP2020519672A5 (enExample) | ||
| Hof et al. | Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma | |
| Gonzalez-Angulo et al. | Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer | |
| CN103533961B (zh) | 以表皮生长因子受体为靶向的治疗癌症的组合方法 | |
| Simo et al. | Nasopharyngeal carcinoma: United Kingdom national multidisciplinary guidelines | |
| de la Rochefordiere et al. | PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy±cetuximab in cervical cancer patients | |
| Rivera et al. | Cetuximab, its clinical use and future perspectives | |
| Pirker et al. | Adjuvant therapy in patients with completely resected non–small-cell lung cancer: current status and perspectives | |
| Luedke et al. | Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation | |
| Qin et al. | Basket trials for intractable cancer | |
| Kim | A narrative review of targeted therapies in meningioma | |
| JP7422084B2 (ja) | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 | |
| Lévi et al. | Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability | |
| Goldwirt et al. | Reply to ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance’by Funck-Brentano et al. | |
| RU2019114031A (ru) | Способы и композиции для tusc2-иммунотерапии | |
| Maione et al. | The role of targeted therapy in non-small cell lung cancer | |
| Stoffel | Targeted therapies for solid tumors: current status and future perspectives | |
| Liubota et al. | The impact of locoregional treatment on survival of patients with primary metastatic breast cancer | |
| Legge et al. | Pharmacotherapy of cervical cancer | |
| WO2018004465A1 (en) | Maintenance therapy for the treatment of cancer | |
| JPWO2022170974A5 (enExample) | ||
| Alzarkali et al. | Ipilimumab and Nivolumab After Disease Progression on Single Agent Immunotherapy in Mismatch Repair Deficient Metastatic Colorectal Cancer | |
| Hammer et al. | Celiac plexus radiosurgery, a new modality for cancer pain management–final results of a phase II clinical trial | |
| RU2021131604A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих инсерции в экзоне 21 her2 |